Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy

L. M. van Roozendaal, B. Goorts*, M. Klinkert, K. B. M. I. Keymeulen, B. de Vries, L. J. A. Strobbe, C. A. P. Wauters, Y. E. van Riet, E. Degreef, E. J. T. Rutgers, J. Wesseling, M. L. Smidt

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Breast cancer guidelines advise sentinel lymph node biopsy (SLNB) in patients with ductal carcinoma in situ (DCIS) on core biopsy at high risk of invasive cancer or in case of mastectomy. This study investigates the incidence of SLNB and SLN metastases and the relevance of indications in guidelines and literature to perform SLNB in order to validate whether SLNB is justified in patients with DCIS on core biopsy in current era. Clinically node negative patients diagnosed from 2004 to 2013 with only DCIS on core needle biopsy were selected from a national database. Incidence of SLN biopsy and metastases was calculated. With Fisher exact tests correlation between SLNB indications and actual presence of SLN metastases was studied. Further, underestimation rate for invasive cancer and correlation with SLN metastases was analysed. 910 patients were included. SLNB was performed in 471 patients (51.8 %): 94.5 % had pN0, 3.0 % pN1mi and 2.5 % pN1. Patients undergoing mastectomy had 7 % SLN metastases versus 3.5 % for breast conserving surgery (BCS) (p = 0.107). The only factors correlating to SLN metastases were smaller core needle size (p = 0.01) and invasive cancer (p <0.001). Invasive cancer was detected in 16.7 % by histopathology with 15.6 % SLN metastases versus only 2 % in pure DCIS. SLNB showed metastases in 5.5 % of patients; 3.5 % in case of BCS (any histopathology) and 2 % when pure DCIS was found at definitive histopathology (BCS and mastectomy). Consequently, SLNB should no longer be performed in patients diagnosed with DCIS on core biopsy undergoing BCS. If definitive histopathology shows invasive cancer, SLNB can still be considered after initial surgery.
Original languageEnglish
Pages (from-to)517-525
JournalBreast Cancer Research and Treatment
Volume156
Issue number3
DOIs
Publication statusPublished - Apr 2016

Keywords

  • DCIS
  • Sentinel lymph node biopsy
  • Incidence
  • Treatment

Fingerprint

Dive into the research topics of 'Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy'. Together they form a unique fingerprint.

Cite this